Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trialRakesh Popat, Jamie Cavenagh, Matthew Streetly et al.|The Lancet Haematology|2016Cited by 43
Time to redefine MyelomaGuy Pratt, Jenny Bird, Stella Bowcock et al.|British Journal of Haematology|2015Cited by 17
Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (<scp>MUK</scp> six open label, multi‐centre phase I/<scp>II</scp> Clinical Trial)Rakesh Popat, Jamie Cavenagh, Eric Low et al.|British Journal of Haematology|2018Cited by 8